🚽 Cranberry & D-Mannose Prevention Evidence Simulator

How Uropathogenic E. coli Attach to the Urothelium

Placeholder: fimbrial tip adhesins recognize host sugar receptors.

• Type 1: Fimbriae type (Placeholder short note)
• FimH: Adhesin protein (Placeholder short note)
• Mannose: Receptor sugar (Placeholder short note)
• ~80%: UTI cause share (Placeholder short note)

FimH tip-adhesin lectin binding

Placeholder: FimH lectin domain binds mannosylated uroplakin receptors.

Catch-bond shear strengthening

Placeholder: flow shear force strengthens the FimH-mannose bond.

Proanthocyanidins Reshape Bacterial Fimbriae

Placeholder: A-type PACs from cranberry hinder fimbrial adhesion.

• A-type PAC: Active compound (Placeholder short note)
• 36 mg/day: Typical dose (Placeholder short note)
• Steric block: Mechanism (Placeholder short note)
• Modest: Cochrane verdict (Placeholder short note)

Anti-adhesive PAC action

Placeholder: PACs alter fimbrial conformation, reducing binding rate.

Dose and standardization issues

Placeholder: product PAC content varies widely across brands.

D-Mannose Competitively Saturates FimH

Placeholder: free mannose sugar outcompetes host receptor mannose.

• D-mannose: Active compound (Placeholder short note)
• 2 g/day: Typical dose (Placeholder short note)
• Competitive: Mechanism (Placeholder short note)
• Renal: Excretion route (Placeholder short note)

FimH lectin-site saturation

Placeholder: excess mannose occupies FimH pockets before bacteria adhere.

Urinary concentration kinetics

Placeholder: rapid renal clearance concentrates mannose in urine.

Comparing Cranberry and D-Mannose Trial Effect Sizes

Placeholder: RCT quality and effect sizes differ between supplements.

• ~26%: Cranberry RRR (Placeholder short note)
• ~50%: Mannose RRR (Placeholder short note)
• Uneven: Trial count (Placeholder short note)
• Low-Mod: Evidence grade (Placeholder short note)

Cochrane cranberry meta-analysis

Placeholder: pooled RCTs show modest, heterogeneous benefit.

D-mannose trial limitations

Placeholder: fewer, smaller trials limit certainty of estimates.

Real-World Preventive Value Depends on Adherence

Placeholder: benefit scales with supplement choice and adherence.

• ~50%: Best case reduction (Placeholder short note)
• Large: Adherence effect (Placeholder short note)
• Adjunct: Guideline status (Placeholder short note)
• Favorable: Safety profile (Placeholder short note)

Adherence-weighted protection

Placeholder: irregular dosing sharply lowers effective protection.

Placement in prevention strategy

Placeholder: used alongside hydration and hygiene measures.

Placeholder: neither replaces antibiotics for active infection.